---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-023806"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:52:42.057884+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Zura Bio presents Phase 2 TibuSURE trial design at SSc World Congress; no data yet

## Summary
- Design of Phase 2 TibuSURE trial evaluating tibulizumab (dual IL-17A/BAFF inhibition) in diffuse cutaneous systemic sclerosis accepted for poster presentation.
- Trial enrolls ~80 adults, randomized 1:1 tibulizumab versus placebo for 24 weeks, then 28-week open-label extension.
- Primary endpoint is change in modified Rodnan Skin Score at Week 24; topline results expected first half 2027.
- No clinical efficacy or safety data will be presented; poster covers rationale and study design only.

## SEC filing metadata
- accession: 0001104659-26-023806
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465926023806/0001104659-26-023806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465926023806/tm268054d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-023806
- JSON: https://secwatch.observer/filing/0001104659-26-023806.json
- Plain text: https://secwatch.observer/filing/0001104659-26-023806.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.